Use access key #2 to skip to page content.
$1.87 -0.03 (-1.60%)
7/24/2008 9:49 AM

IDM Pharma, Inc. (IDMI)

CAPS Rating:
No stars

A biopharmaceutical company focused on developing innovative products to treat and control cancer while maintaining the patient's quality of life.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

IDMI doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

10 Outperforms
2 Underperforms
 

All-Stars

2 Outperforms
1 Underperforms
 

Members bullish on IDMI are also bullish on:

Members bearish on IDMI are also bearish on:

Ticker Tags

Biotechnology (294), Micro Cap (4824)
Suggest a tag

IDM Pharma, Inc. At A Glance

Current Price: $1.87
Last Trade Time: 7/24/2008 9:49 AM
Open: $1.84
Previous Close: $1.87
Daily Range: $1.83 - $1.87
52-Week Range: $0.57 - $3.88
Volume: 1,728
Market Cap: $47.07M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

IDMI VS S&P 500 (SPY)

IDMI 12 month chart vs. S&P

News & Discussion Boards

Sorry no news articles available for IDMI.

Top Bull Pitch

Recs

1

IDM Pharma, Inc. (IDMI)

Avatar mac1787 (< 20) Submitted: 4/04/07 4:30 PM

I was ready to sell, therefore it must go up!

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 4 of 4  

Recs

0

 (IDMI)

Avatar hleason (< 20) Submitted: 5/02/07 12:09 PM : Outperform Start Price: $8.19 IDMI Score: -63.08

But MTPPE, JUVANAN, is due for FDA panel review on 5/9/07. I believe that they will recommend approval. The stock should sell up big on this news, maybe 20+. It may cool a little after that, but maybe not. JUVANAN is MTPPE and showed a survival benefit with minimal and non serious side effects.


Since it is an injection to stimulate macrophage cells, it could be used for all cancers, not just osteosarcoma. The approval, if so, would be for osteosarcoma, about 1000 cases in the US per year.


This is very small, but off label is really very large. You don't hear much about this now since the FDA hasn't passed on Juvanan yet, and they don't like pre-approval speculation about off label use.


But it is my opinion that Junanan, if approved, will eventually be used off label and that it will prove to be useful in the treatment of virtually all cancers. This would be a home run.





Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (IDMI)

Avatar mac1787 (< 20) Submitted: 4/04/07 4:30 PM : Outperform Start Price: $6.89 IDMI Score: -61.75

I was ready to sell, therefore it must go up!

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (IDMI)

Avatar olemt (50.91) Submitted: 4/04/07 11:05 AM : Outperform Start Price: $8.16 IDMI Score: -66.52

Another cancer treatment bullrun.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (IDMI)

Avatar bdbartle (60.57) Submitted: 4/04/07 10:38 AM : Outperform Start Price: $8.81 IDMI Score: -68.17

Sure. Why not.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 4 of 4  

Wall Street

There are no Wall Street tracker picks.

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners